HighPoint Advisor Group LLC lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 37.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,218 shares of the medical research company’s stock after buying an additional 1,705 shares during the period. HighPoint Advisor Group LLC’s holdings in Amgen were worth $1,221,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Beutel Goodman & Co Ltd. bought a new stake in shares of Amgen in the 2nd quarter valued at about $86,723,000. Natixis grew its position in shares of Amgen by 2,612.1% in the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after buying an additional 510,281 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in shares of Amgen by 775.0% during the 1st quarter. Old Mutual Global Investors UK Ltd. now owns 532,015 shares of the medical research company’s stock valued at $90,697,000 after purchasing an additional 471,216 shares in the last quarter. Summit Trail Advisors LLC boosted its position in shares of Amgen by 16,458.8% during the 1st quarter. Summit Trail Advisors LLC now owns 433,510 shares of the medical research company’s stock valued at $434,000 after purchasing an additional 430,892 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Amgen by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after purchasing an additional 343,690 shares in the last quarter. 82.48% of the stock is owned by institutional investors.

Shares of Amgen stock traded up $3.54 on Friday, hitting $197.39. The company had a trading volume of 2,784,524 shares, compared to its average volume of 3,571,043. The company has a market cap of $134.17 billion, a PE ratio of 15.69, a price-to-earnings-growth ratio of 2.02 and a beta of 1.40. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating the Zacks’ consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. Amgen’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the business posted $3.27 earnings per share. As a group, research analysts anticipate that Amgen, Inc. will post 13.96 EPS for the current year.

Several equities research analysts recently commented on the company. Oppenheimer restated a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Tuesday, October 2nd. Jefferies Financial Group restated a “buy” rating and set a $220.00 target price on shares of Amgen in a research report on Friday, August 24th. Morgan Stanley upped their target price on Amgen from $210.00 to $212.00 and gave the company an “overweight” rating in a research report on Thursday. Leerink Swann set a $209.00 target price on Amgen and gave the company a “hold” rating in a research report on Monday, September 17th. Finally, Cantor Fitzgerald set a $223.00 target price on Amgen and gave the company a “neutral” rating in a research report on Monday, October 8th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $204.90.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.27% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: What is a Leveraged Buyout (LBO)?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.